Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles

Neuropharmacology

Volumn 35, Issue 12, 1996, Pages 1689-1702

  Bleakman, David ^a   Ballyk, Barbara A ^b   Schoepp, Darryle D ^a   Palmer, Andrew J ^a   Bath, Catherine P ^a   Sharpe, Erica F ^a   Woolley, Marie L ^a   Bufton, Hywel R ^c   Kamboj, Rajender K ^b   Tarnawa, Istvan ^d   Lodge, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NPS Pharmaceutical Inc   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Institute for Drug Research Budapest   (Hungary)

Author keywords

cortical wedge; dorsal root ganglion; GluR1; GluR4; GluR5; GluR6; GluR6+KA2; GYKI52466; GYKI53405; GYKI53655; LY293606; LY300168; NMDA; Purkinje neurons; spinal cord

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BENZODIAZEPINE DERIVATIVE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENANTIOMER; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL GANGLION; STEREOSPECIFICITY;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BENZOTHIADIAZINES; CELL LINE; CEREBELLUM; CEREBRAL CORTEX; EXCITATORY AMINO ACID ANTAGONISTS; GANGLIA, SPINAL; HUMANS; KIDNEY; MEMBRANE POTENTIALS; MOLECULAR STRUCTURE; NEURONS; PURKINJE CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECOMBINANT PROTEINS; SPINAL CORD; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0030483692     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00156-6     Document Type: Article

References (38)

1. Agrawal S.G., Evans R.H. The primary afferent depolarizing actions of kainate in the rat. Br. J. Pharmacol. 87:1986;345-355.
2. Bleakman D., Schoepp D.D., Ballyk B., Bufton H., Sharpe E.F., Thomas K., Ornstein P.L., Kamboj R.K. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S, 5aR, 6R, 8aR)-6-[2-((1(2) H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid. Molec. Pharmacol. 49:1996;581-585.
3. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate nervous system. Pharmacol. Rev. 40:1989;143-210.
4. Danysz N., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drugs New Perspect. 8:1995;261-277.
5. Desai M.A., Burnett J.P., Ornstein P.L., Schoepp D.D. Cyclothiazide acts at a site on the α-amino-3 hydroxy-5-methyl-4-isoxazole propionic receptor complex that does not recognise competitive or non-competitive AMPA receptor antagonists. J. Pharmacol. Exp. Ther. 272:1995;38-43.
6. Donevan S.D., Yamaguchi S., Rogawski M.A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines; relationship to anti-convulsant activity. J. Pharmacol. Exp. Ther. 271:1994;25-29.
7. Fletcher E.J., Nutt S.L., Hoo K.H., Elliot C.E., Korczak B., McWhinnie E.A., Kamboj R.K. Cloning, expression and pharmacological characterization of a human glutamate receptor: hGluR4. Recept. Channels. 3:1995;21-31.
8. Hamill O., Marty A., Neher E., Sakmann B., Sigworth F. An improved patch clamp technique for high resolution current recordings from cell and cell free membrane patches. Pflügers Arch. 391:1981;85-100.
9. Hollman M., Heinemann S. Cloned glutamate receptors. Ann. Rev. Neurosci. 17:1994;31-108.
10. Hoo K., Nutt S., Fletcher E.F., Elliot C., Korczack B., Deverill M., Rampersand V., Fantaske R.P., Kamboj R.K. Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit. Recept. Channels. 2:1994;327-337.
11. Huettner J.E. Glutamate receptor channels in DRG neurons; activation by kainate and quisqualate and blockade of desensitization by concanavalin A. Neuron. 5:1990;255-266.
12. Johansen T.H., Chaudhary A., Verdoorn T.A. Interactions among GYKI 52466, cyclothiazide and aniracetam at recombinant AMPA and kainate receptors. Molec. Pharmacol. 48:1995;946-955.
13. Kamboj R.K., Schoepp D.D., Nutt S., Schekter L., Korczak B., True R.A., Zimmerman D.M., Wosnick M.A. Molecular structure and pharmacological chracterization of humEAA2, a novel human kainate receptor subunit. Molec. Pharmacol. 42:1992;10-15.
14. Korczak B., Nutt S.L., Fletcher E.J., Hoo K.H., Elliot C.E., Rampersand V., McWhinnie E.A., Kamboj R.K. cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. Recept. Channels. 3:1995;41-49.
15. Lerma J., Paternain A.V., Naranjo J.R., Melstrom B. Functional kainate selective glutamate receptors in cultured hippocampal neurons. Proc. Natn. Acad. Sci. U.S.A. 90:1993;11688-11692.
16. Lodge D., Bond A., O'Neill M.J., Hicks C.A., Jones M.G. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology. 35:1996;1681-1688.
17. Lodge D., Jones M.G., Palmer A.J. and Zeman S. (1992) Electrophysiology of glutamate receptors, In: Drug Research Related to Neuroactive Amino Acids, A. Schousboe, N.H. Diemer and J. Kufod, Eds.) p.153, Munksgaard, Copenhagen.
18. Mintz I.M., Venema V.J., Swiderick K.M., Lee T.D., Bean B.P., Adams M.E. Block of P-type calcium channels by funnel web spider toxin ω-Aga-IVA. Nature. 355:1992;827-829.
19. Moises H.C., Rusin K.I., McDonald R.J. u-opioid receptor mediated reductions in neuronal calcium channel currents occurs via a G0 type GTP binding protein. J. Neurosci. 14:1994;3842-3851.
20. Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation and plasticity. Neuron. 13:1994;1031-1037.
21. Osipenko O., Mike A., Gyevai A., Vizi E.S. Evidence for GYKI52466, a novel NMDA antagonist enhances the decay of kainate-induced current in cultured chicken cortical neurons. Brain. Res. Devel. Brain Res. 77:1994;257-263.
22. Ourdouz M., Durand J. GYKI 52466 antagonizes glutamate responses but not NMDA and kainate responses in rat abducens motoneurons. Neurosci. Lett. 125:1991;5-8.
23. Ourdouz M., Durand J. Involvment of AMPA receptors in trigeminal postsynaptic potentials recorded in rat motoneurons in vivo. Eur. J. Neurosci. 6:1993;1662-1668.
24. Palmer A.J., Lodge D. Cyclothiazide reverses AMPA receptor antagonism of the 2,3 benzodiazepine, GYKI53655. Eur. J. Pharmacol. 244:1993;193-194.
25. Partin K.M., Patneau D.K., Winters A., Mayer M.L., Buonanno A. Selective modulation of desensitization at AMPA versus kainate receptors by cyclothizide and concanavalin A. Neuron. 11:1993;1069-1082.
26. Partin K.M., Mayer M.A. Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655. Molec. Pharmacol. 49:1996;142-148.
27. Paternain A.V., Morales M., Lerma J. Selective antagonism of AMPA receptors unmasks kainate-receptor mediated responses in hippocampal neurons. Neuron. 14:1995;185-189.
28. Petralia R.S., Wenthold R.J. Light and electron immunocytochemical localization of AMPA selective receptors in the rat brain. J. Comp. Neurol. 318:1992;329-354.
29. Pelligrini-Giampietro D.E., Bennet M.V.L., Zukin R.S. Differential expression of three glutamate receptor genes in developing rat brain: an in situ hybridization study. Proc. natn. Acad. Sci. U.S.A. 88:1991;4147-4161.
30. Rammes G., Swandulla D., Collingridge G.L., Hartmann S., Parsons C.G. Interactions of 2,3 benzodiazepines and cyclothiazide at AMPA receptors; patch clamp recordings in cultured neurons and area CA1 in hippocampal slices. Br. J. Pharmacol. 117:1996;1209-1221.
31. Rogawski M.A. Therapetic potential of excitatory amino acid antagonists; channel blockers and 2,3 benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
32. Sheardown M.J., Nielson E.O., Jacobson P., Honore T. 2,3 dihydroxy-6-nitro-7-sulfamoyl-benzo-F quinoxaline: a new neuroprotectant for ischemia. Science. 247:1990;571-574.
33. Tarnawa I., Berzsenyi P., Andrasi F., Botka P., Hamori T., Ling I., Korosi J. Structure activity relationships of 2,3-benzodiazepine compounds with glutamate antagonist action. Bioorg. Med. Chem. Lett. 3:1993;99-104.
34. Vizi E.S., Mike I., Tarnawa I. 2,3-Benzodiazepines (GYKI52466 and analogues): negative allosteric modulators of AMPA receptors. CNS Drug Rev. 2:1996;91-126.
35. Watkins J.C., Krogsgaard-Larson P., Honore T. Structure activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 11:1990;25-33.
36. Wilding T.J., Huettner J.E. Differential antagonism of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid preferring and kainate preferring receptors by 2,3-benzodiazepines. Molec. Pharmacol. 47:1995;582-587.
37. Yamada K.A., Turetsky D.M. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists. Br. J. Pharmacol. 117:1996;1663-1672.
38. Zorumski C.F., Yamada K.A., Price M.T., Olney J.N. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron. 10:1993;61-67.